Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Korro Bio, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing innovative genetic medicines through RNA editing [1]. Company Overview - Korro Bio is a biopharmaceutical company dedicated to creating a new class of genetic medicines aimed at treating both rare and common diseases [3]. - The company is developing a portfolio of programs that utilize the body's natural RNA editing process, allowing for precise and transient single base edits [3]. - By focusing on RNA editing rather than DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to improved specificity and long-term tolerability [3]. - Korro plans to leverage its proprietary platform, established regulatory pathways, and manufacturing expertise to bring its oligonucleotide-based medicines to patients [3]. Investor Relations - Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) for disclosing material nonpublic information and fulfilling its disclosure obligations under Regulation FD [4]. - Investors are encouraged to monitor Korro's Investor Relations website and follow its social media channels for updates and information [4].